Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?
Policy Change and the National Essential Medicines List Development Process in Brazil between...
Osorio‐de‐Castro, Claudia G. S.; Azeredo, Thiago B.; Pepe, Vera L. E.; Lopes, Luciane C.; Yamauti, Sueli; Godman, Brian; Gustafsson, Lars L.
2018-01-01 00:00:00
Brazil has had a National Essential Medicines List (EML) since 1964. From 2000 to 2010, five consecutive evidence‐based editions were produced, building on the essential medicine concept. In 2012, the government changed course to establish a new paradigm, introducing adoption of new medicines as the main aim within the recommendation process. The objective of the article was to report efforts to develop Brazil's national EML, policy changes from 2000 to 2014, discussing results, challenges and perspectives. Brazilian EML history and development process were collected from legislation, minutes, reports and legal ordinances, from 2000 to 2014. The Brazilian EML and the WHO Model Lists were compared using the Anatomical Therapeutic Chemical system. Overlap between lists was verified, and linear trends were produced. Type of membership, inclusion criteria, procedures, flow and listed medicines varied greatly between the selection committees acting before and after 2012. Paradigm‐changing legislation aiming at linking list compliance to public financing in 2012 produced (i) greater importance given to political and administrative stakeholders, (ii) increasing trends in number of medicines over the years, (iii) decrease in use of WHO Model List as a reference and (iv) substitution of an essential medicines list review and update process by an adoption decision output. Other issues remained unchanged. Insufficient efforts for list implementation, such as lack of physician education, presented consequences to the health system. Substantial efforts were made to produce and update the list from 2000 to 2014. However, continuous and intense health litigation disproves process outcome effectiveness.
http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.pngBasic and Clinical Pharmacology & ToxicologyWileyhttp://www.deepdyve.com/lp/wiley/policy-change-and-the-national-essential-medicines-list-development-GYCemffFqe
Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?
Brazil has had a National Essential Medicines List (EML) since 1964. From 2000 to 2010, five consecutive evidence‐based editions were produced, building on the essential medicine concept. In 2012, the government changed course to establish a new paradigm, introducing adoption of new medicines as the main aim within the recommendation process. The objective of the article was to report efforts to develop Brazil's national EML, policy changes from 2000 to 2014, discussing results, challenges and perspectives. Brazilian EML history and development process were collected from legislation, minutes, reports and legal ordinances, from 2000 to 2014. The Brazilian EML and the WHO Model Lists were compared using the Anatomical Therapeutic Chemical system. Overlap between lists was verified, and linear trends were produced. Type of membership, inclusion criteria, procedures, flow and listed medicines varied greatly between the selection committees acting before and after 2012. Paradigm‐changing legislation aiming at linking list compliance to public financing in 2012 produced (i) greater importance given to political and administrative stakeholders, (ii) increasing trends in number of medicines over the years, (iii) decrease in use of WHO Model List as a reference and (iv) substitution of an essential medicines list review and update process by an adoption decision output. Other issues remained unchanged. Insufficient efforts for list implementation, such as lack of physician education, presented consequences to the health system. Substantial efforts were made to produce and update the list from 2000 to 2014. However, continuous and intense health litigation disproves process outcome effectiveness.
Journal
Basic and Clinical Pharmacology & Toxicology
– Wiley
Published: Jan 1, 2018
Recommended Articles
Loading...
References
The Selection of Essential Drugs: First Report of the WHO Expert Committee
The concept of essential medicines: lessons for rich countries
The “Wise List”‐ a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm
Quality use of medicines within universal health coverage: challenges and opportunities
Wagner, AK; Quick, JD; Ross‐Degnan, D
Essential medicines for universal health coverage
Wirtz, VJ; Hogerzeil, HV; Gray, AL; Bigdeli, M; Joncheere, CP; Ewen, MA
High adherence to the ‘Wise List' treatment recommendations in Stockholm: a 15‐year retrospective review of a multifaceted approach promoting rational use of medicines
Induction of hospital indebtedness due to medicine purchases under monopoly conditions: the case of imatinib mesylate
Scopel, CT; Chaves, GC
Legal access to medications: a threat to Brazil's public health system?
Chieffi, AL; Barata, RCB; Golbaum, M
Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?
Grössmann, N; Wild, C
Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care
Kelly, RJ; Smith, TJ
You’re reading a free preview. Subscribe to read the entire article.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”
Daniel C.
“Whoa! It’s like Spotify but for academic articles.”
@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”
@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Subscribe to Journal Email Alerts
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
Follow a Journal
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.